Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...